{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:16:29Z","timestamp":1777072589730,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ecl.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:02:51Z","timestamp":1761087771000},"page":"627-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Medical Therapies of Cushing\u2019s Disease\u2013Part 2"],"prefix":"10.1016","volume":"54","author":[{"given":"Yair","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reut","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ecl.2025.08.003_bib1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2025.08.003_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41574-023-00868-7","article-title":"An individualized approach to the management of cushing disease","volume":"19","author":"Fleseriu","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.003_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/EJE-20-0380","article-title":"Etomidate infusion at low doses is an effective and safe treatment for severe Cushing\u2019s syndrome outside intensive care","volume":"183","author":"Constantinescu","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.003_bib4","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1210\/clinem\/dgac691","article-title":"Efficacy and safety of osilodrostat in paraneoplastic cushing syndrome: a real-world multicenter study in France","volume":"108","author":"Dormoy","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2025.08.003_bib5","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating cushing\u2019s syndrome: a retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2025.08.003_bib6","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.003_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.7326\/0003-4819-114-2-143","article-title":"Rapid reversal of acute psychosis in the cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486)","volume":"114","author":"van der Lely","year":"1991","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.003_bib8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s11102-022-01263-7","article-title":"Levoketoconazole in the treatment of patients with endogenous Cushing\u2019s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)","volume":"25","author":"Pivonello","year":"2022","journal-title":"Pituitary"},{"issue":"10","key":"10.1016\/j.ecl.2025.08.003_bib9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.003_bib10","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing\u2019s disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.003_bib11","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf046","article-title":"Osilodrostat treatment of cushing syndrome in real-world clinical practice: findings from the ILLUSTRATE study","volume":"9","author":"Fleseriu","year":"2025","journal-title":"J Endocr Soc"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.003_bib12","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.003_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40842-020-00105-4","article-title":"Clinical management of patients with cushing syndrome treated with mifepristone: consensus recommendations","volume":"6","author":"Brown","year":"2020","journal-title":"Clin diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.003_bib14","article-title":"Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition","volume":"256","author":"Viho","year":"2023","journal-title":"J Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2025.08.003_bib15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-12-0358","article-title":"Efficiency and tolerance of mitotane in Cushing\u2019s disease in 76 patients from a single center","volume":"167","author":"Baudry","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2025.08.003_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-22-0317","article-title":"Long-term outcomes of osilodrostat in Cushing\u2019s disease: LINC 3 study extension","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ecl.2025.08.003_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1236465","article-title":"Long-term efficacy and safety of osilodrostat in patients with Cushing\u2019s disease: results from the LINC 4 study extension","volume":"14","author":"Gadelha","year":"2023","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.003_bib18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1530\/EJE-22-0506","article-title":"Levoketoconazole treatment in endogenous Cushing\u2019s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.003_bib19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s12020-017-1316-3","article-title":"Long-term treatment of Cushing\u2019s disease with pasireotide: 5-year results from an open-label extension study of a phase III trial","volume":"57","author":"Petersenn","year":"2017","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.003_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","article-title":"Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial","volume":"6","author":"Lacroix","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ecl.2025.08.003_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-015-0059-5","article-title":"Sustained weight loss in patients treated with mifepristone for Cushing\u2019s syndrome: a follow-up analysis of the SEISMIC study and long-term extension","volume":"15","author":"Fein","year":"2015","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.ecl.2025.08.003_bib22","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.eprac.2024.09.061","article-title":"Abstract #1885059 open-label extension study evaluating the safety and efficacy of long-term use of relacorilant in patients with endogenous hypercortisolism (cushing syndrome): results from the first interim analysis","volume":"30","author":"Schlafly","year":"2024","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ecl.2025.08.003_bib23","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.110.P3","article-title":"Relacorilant improved blood pressure and maintained other cardiometabolic improvements in long-term study in patients with endogenous hypercortisolism (cushing syndrome)","author":"Badiu","year":"2025","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.ecl.2025.08.003_bib24","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.90.EP801","article-title":"An open-label extension study to evaluate the safety of long-term use of relacorilant in patients with endogenous cushing syndrome","author":"Badiu","year":"2023","journal-title":"Endocr Abstr"},{"issue":"3","key":"10.1016\/j.ecl.2025.08.003_bib25","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1093\/ejendo\/lvae110","article-title":"How to manage Cushing\u2019s disease after failed primary pituitary surgery","volume":"191","author":"Agrawal","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2025.08.003_bib26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the medical treatment of Cushing\u2019s syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2025.08.003_bib27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/clinem\/dgac588","article-title":"Treatment of cushing disease with pituitary-targeting seliciclib","volume":"108","author":"Liu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2025.08.003_bib28","doi-asserted-by":"crossref","first-page":"E997","DOI":"10.1210\/jc.2015-1453","article-title":"The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing cushing\u2019s disease","volume":"100","author":"Perez-Rivas","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.003_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ng.3166","article-title":"Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease","volume":"47","author":"Reincke","year":"2015","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.003_bib30","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1210\/clinem\/dgaa699","article-title":"Targeting corticotroph HDAC and PI3-kinase in cushing disease","volume":"106","author":"Zhang","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.003_bib31","first-page":"1","article-title":"ALD1613, a novel long-acting monoclonal antibody to control ACTH-Driven pharmacology","volume":"158","author":"Feldhaus","year":"2017","journal-title":"Endocrinology"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2025.08.003_bib32","article-title":"9330 atumelnant (crn04894) induces rapid and sustained reductions in serum and urine cortisol in patients with acth-dependent cushing syndrome during a phase 1b\/2a, single center, 10-day, inpatient, open-label study","volume":"8","author":"Elenius","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ecl.2025.08.003_bib33","article-title":"Clofutriben, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, vs. Placebo in a phase II trial for ACTH-Dependent Cushing\u2019s syndrome (RESCUE)","author":"Fleseriu","year":"2025","journal-title":"Oral presentation Endocrine Society San Fransisco"},{"issue":"7","key":"10.1016\/j.ecl.2025.08.003_bib34","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1210\/clinem\/dgad098","article-title":"Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment","volume":"108","author":"Burman","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2025.08.003_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.732240","article-title":"Effectiveness of medical treatment of cushing\u2019s disease: a systematic review and meta-analysis","volume":"12","author":"Sim\u00f5es Corr\u00eaa Galendi","year":"2021","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.003_bib36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/14656566.2023.2192349","article-title":"An evaluation of pharmacological options for Cushing\u2019s disease: what are the state-of-the-art options?","volume":"24","author":"Martino","year":"2023","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"10.1016\/j.ecl.2025.08.003_bib37","first-page":"1","article-title":"Budget impact analysis of cabergoline for medical treatment of Cushing\u2019s disease in Brazil","volume":"68","author":"de Silva","year":"2024","journal-title":"Arch Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.003_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11102-013-0475-3","article-title":"Combination therapy for Cushing\u2019s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?","volume":"17","author":"Barbot","year":"2014","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.003_bib39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary"},{"issue":"19","key":"10.1016\/j.ecl.2025.08.003_bib40","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in cushing\u2019s disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N Engl J Med"},{"issue":"October","key":"10.1016\/j.ecl.2025.08.003_bib41","first-page":"1","article-title":"Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing\u2019s disease","volume":"14","author":"Feelders","year":"2023","journal-title":"Front Endocrinol"},{"issue":"7","key":"10.1016\/j.ecl.2025.08.003_bib42","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf089","article-title":"A prospective trial with ketoconazole induction therapy and octreotide maintenance treatment for cushing\u2019s disease","volume":"9","author":"Paes","year":"2025","journal-title":"J Endocr Soc"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.003_bib43","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s11102-022-01244-w","article-title":"Cushing\u2019s disease: role of preoperative and primary medical therapy","volume":"25","author":"Castinetti","year":"2022","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.003_bib44","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1055\/s-0044-1786740","article-title":"The effect of preoperative cabergoline on prolactinoma fibrosis: a case series","volume":"85","author":"Pecorari","year":"2024","journal-title":"J Neurol Surg reports"},{"issue":"3","key":"10.1016\/j.ecl.2025.08.003_bib45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.23736\/S2724-6507.21.03622-8","article-title":"The effects of cabergoline in the presurgical and recurrence periods of Cushing\u2019s disease patients","volume":"49","author":"Pereira","year":"2024","journal-title":"Minerva Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.003_bib46","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cen.13600","article-title":"Worse health-related quality of life at long-term follow-up in patients with Cushing\u2019s disease than patients with cortisol producing adenoma. Data from the ERCUSYN","volume":"88","author":"Valassi","year":"2018","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ecl.2025.08.003_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1230447","article-title":"Emerging diagnostic methods and imaging modalities in cushing\u2019s syndrome","volume":"14","author":"Wright","year":"2023","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.003_bib48","doi-asserted-by":"crossref","first-page":"688","DOI":"10.2967\/jnumed.123.266853","article-title":"[(18)F]FET PET\/MRI: an accurate technique for detection of small functional pituitary tumors","volume":"65","author":"Pruis","year":"2024","journal-title":"J Nucl Med"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T03:34:23Z","timestamp":1772940863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852925000805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0889852925000805"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2025.08.003","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Therapies of Cushing\u2019s Disease\u2013Part 2","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}